Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Gotlib

Showing results (11-20 of 246) with videos related to

Pageof 25
Sort By:
Blood|July 15, 2017
A molecular roadmap for midostaurin in mastocytosisJason Gotlib
American Journal of Hematology|October 19, 2017
World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and managementJason Gotlib
Blood|March 19, 2026
Introduction to a review series on the new wave of targeted therapeutics for MPNsJason Gotlib
Immunology and Allergy Clinics of North America|August 26, 2006
KIT mutations in mastocytosis and their potential as therapeutic targetsJason Gotlib
Blood|November 9, 2023
Introduction to a review series on RNA therapeutics in hematologyJason Gotlib
Blood|March 10, 2022
Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truthJason Gotlib
Therapeutic Advances in Hematology|August 9, 2013
EditorialJason Gotlib
Blood|April 17, 2025
Introduction to a How I Treat series on myeloproliferative neoplasmsJason Gotlib
American Journal of Hematology|August 29, 2012
World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and managementJason Gotlib
American Journal of Hematology|November 10, 2009
On being metachromatic: mystique and misunderstanding in mastocytosisJason Gotlib
Pageof 25

Showing results (11-20 of 246) with videos related to

Sort By:
Pageof 25
Blood|July 15, 2017
A molecular roadmap for midostaurin in mastocytosisJason Gotlib
American Journal of Hematology|October 19, 2017
World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and managementJason Gotlib
Blood|March 19, 2026
Introduction to a review series on the new wave of targeted therapeutics for MPNsJason Gotlib
Immunology and Allergy Clinics of North America|August 26, 2006
KIT mutations in mastocytosis and their potential as therapeutic targetsJason Gotlib
Blood|November 9, 2023
Introduction to a review series on RNA therapeutics in hematologyJason Gotlib
Blood|March 10, 2022
Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truthJason Gotlib
Therapeutic Advances in Hematology|August 9, 2013
EditorialJason Gotlib
Blood|April 17, 2025
Introduction to a How I Treat series on myeloproliferative neoplasmsJason Gotlib
American Journal of Hematology|August 29, 2012
World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and managementJason Gotlib
American Journal of Hematology|November 10, 2009
On being metachromatic: mystique and misunderstanding in mastocytosisJason Gotlib
Pageof 25